Eldecalcitol, a new vitamin D medication, significantly improved bone density and lowered bad cholesterol levels in 54 postmenopausal women with osteoporosis over 24 weeks. According to Gram Research analysis, LDL-cholesterol decreased significantly, and liver function markers also improved, suggesting this single medication may address multiple health concerns common in postmenopausal women.
Researchers tested a new vitamin D medication called eldecalcitol on 54 postmenopausal women with weak bones (osteoporosis) for 24 weeks. According to Gram Research analysis, the drug not only strengthened their bones significantly but also lowered their bad cholesterol levels and improved other markers of metabolic health. This is the first clinical study to show that eldecalcitol might help with cholesterol and liver function alongside treating bone loss, suggesting this single medication could address multiple health problems common in older women.
Key Statistics
A 2026 clinical investigation of 54 postmenopausal women found that eldecalcitol treatment for 24 weeks significantly improved bone density in both the lumbar spine and femoral neck with P-values less than 0.001.
In the same 54-woman study, eldecalcitol reduced LDL-cholesterol levels significantly with a P-value of 0.007, indicating less than 1 percent probability the improvement occurred by chance.
A 2026 study of 54 osteoporosis patients showed that eldecalcitol improved liver function markers and blood sugar control within 24 weeks, suggesting benefits beyond bone strengthening alone.
The Quick Take
- What they studied: Whether a new vitamin D medication called eldecalcitol could strengthen bones and improve cholesterol and other metabolic markers in postmenopausal women with osteoporosis
- Who participated: 54 postmenopausal women who had never been treated for osteoporosis before and had weak bones confirmed by bone density scans
- Key finding: After 24 weeks of taking eldecalcitol, women’s bone density improved significantly, bad cholesterol (LDL) dropped by a meaningful amount, and markers of liver and blood sugar health also improved
- What it means for you: This medication may offer postmenopausal women a single treatment that addresses multiple health concerns at once, though larger studies are needed to confirm these benefits before it becomes standard treatment
The Research Details
Researchers recruited 54 postmenopausal women with osteoporosis who had never taken bone-strengthening medications before. Each woman received a daily dose of eldecalcitol (0.75 micrograms) for 24 weeks without changing any of their other medications. The researchers measured bone density, cholesterol levels, blood sugar control, and liver function at the start and end of the study.
This type of study is called a clinical investigation or observational study. It doesn’t compare the medication to a placebo or control group, so researchers can only describe what happened to the women who took it, not prove the medication caused the improvements. However, it provides valuable early evidence about how the drug affects the body.
Previous research showed that vitamin D can help bones and improve blood sugar control, but no one had studied whether this specific new vitamin D medication affected cholesterol. This study fills that gap by being the first to measure cholesterol changes with eldecalcitol, which is important because postmenopausal women often have both weak bones and high cholesterol.
All 54 women completed the study without serious problems, which is a positive sign. However, the study had no control group for comparison, so we cannot be certain the medication caused the improvements rather than other factors. The researchers used proper statistical methods to analyze the data, and they acknowledged that larger, controlled studies are needed to confirm these findings.
What the Results Show
Bone density improved significantly in both the lower spine and hip after 24 weeks of eldecalcitol treatment. The T-scores, which measure bone strength, showed clear improvement with very strong statistical evidence (P less than 0.001, meaning there is less than a 0.1 percent chance this happened by random chance).
Bad cholesterol (LDL-cholesterol) levels decreased significantly after the treatment, with a P-value of 0.007. This means there is less than a 1 percent chance this improvement happened randomly. Blood sugar control also improved, shown by lower glycated hemoglobin levels, which measures average blood sugar over several months.
Liver function markers also improved, with decreases in two different liver enzymes (alanine aminotransferase and gamma-glutamyl transferase). These improvements suggest the medication may help the liver work better, not just the bones.
When researchers performed additional statistical tests to check their results, the cholesterol improvement showed a trend toward significance but did not quite reach the threshold for definitive proof (P equals 0.056). This suggests the finding is promising but needs confirmation in larger studies. The study found no connection between age, body weight, or the degree of metabolic improvement and how much bone density improved, suggesting the bone benefits work through a different mechanism than the metabolic benefits.
Previous research showed that activated vitamin D can improve blood sugar tolerance and liver function, and this study confirms those findings with eldecalcitol specifically. However, this is the first clinical study to examine whether this type of vitamin D medication affects cholesterol levels, making it a novel contribution to the research. The bone-strengthening effects align with what researchers expected from vitamin D medications.
The study had no control group, meaning we cannot compare the results to women who did not take the medication or took a placebo. This makes it impossible to know if the improvements were caused by eldecalcitol or by other factors like lifestyle changes or natural variation. The study included only 54 women and lasted only 24 weeks, which is relatively short. The study did not track whether benefits continued after stopping the medication or how long they lasted. Researchers acknowledged these limitations and called for larger, controlled studies to confirm the findings.
The Bottom Line
Eldecalcitol shows promise for postmenopausal women with osteoporosis who also have high cholesterol or metabolic concerns, but current evidence is preliminary. This medication should only be considered under a doctor’s supervision as part of a comprehensive treatment plan. Confidence level: Low to Moderate. Larger controlled trials are needed before this becomes standard treatment.
Postmenopausal women with osteoporosis, especially those who also have high cholesterol or liver function concerns, should discuss eldecalcitol with their doctor. Women with normal bone density or those already taking other osteoporosis medications should not assume this applies to them without medical consultation. Men and premenopausal women were not studied.
Bone density improvements appeared within 24 weeks, which is relatively quick. Cholesterol and liver function improvements also appeared within this timeframe. However, the study did not track whether these benefits continue beyond 24 weeks or how long they last after stopping the medication.
Frequently Asked Questions
Does vitamin D medication help with cholesterol in postmenopausal women?
Research shows eldecalcitol, a new vitamin D medication, reduced LDL-cholesterol significantly in 54 postmenopausal women over 24 weeks. However, larger controlled studies are needed to confirm this effect before it becomes standard treatment.
How quickly does eldecalcitol strengthen bones in women with osteoporosis?
Bone density improvements appeared within 24 weeks of daily eldecalcitol treatment in this study, with significant increases in T-scores at both the spine and hip. Long-term benefits beyond 24 weeks require further research.
Can one medication treat both osteoporosis and high cholesterol?
Eldecalcitol shows promise for addressing both conditions simultaneously, improving bone density and lowering bad cholesterol in the same 24-week period. However, this was a preliminary study without a control group, so larger trials are needed.
What are the side effects of eldecalcitol based on this study?
All 54 women in this study completed treatment without complications or serious side effects reported. However, this study was not designed to comprehensively track side effects, so consult your doctor about potential risks.
Is eldecalcitol better than regular vitamin D for osteoporosis?
This study tested eldecalcitol specifically but did not compare it to regular vitamin D or other osteoporosis medications. Larger comparative studies would be needed to determine if it is more effective than alternatives.
Want to Apply This Research?
- Track weekly cholesterol-related markers if available through lab work, bone pain or discomfort levels on a 1-10 scale, and energy levels to monitor overall metabolic health changes over the 24-week treatment period
- Users taking eldecalcitol should log daily medication adherence, dietary calcium and vitamin D intake, and any side effects or improvements noticed to create a comprehensive health picture alongside the medication
- Set reminders for regular lab work to monitor LDL cholesterol, liver enzymes, and blood sugar markers every 8-12 weeks, and schedule bone density scans annually to track long-term bone strength improvements
This research is preliminary and was conducted in a small group of 54 women without a control group for comparison. Eldecalcitol is not yet widely available or approved for routine use in all countries. Do not start, stop, or change any osteoporosis or cholesterol medication without consulting your doctor. This article summarizes research findings and should not be interpreted as medical advice. Individual results may vary, and larger controlled studies are needed to confirm these findings before eldecalcitol becomes standard treatment.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.